Pregnancy Outcomes and Management in Lung and Heart Transplant Recipients: A Systematic Review

Tanaka,A.,Filippidis,F. T.,El Asmar,M. L.,Reed,A.,Gerovasili,V.
DOI: https://doi.org/10.1183/13993003.congress-2024.pa4987
IF: 24.3
2024-11-01
European Respiratory Journal
Abstract:Introduction: Immunosuppression advances have enabled organ transplant recipients to consider parenthood, but pregnancy poses risks to maternal and fetal health. Aim: This is a systematic review on pregnancy outcomes and immunosuppression management in cardiothoracic transplant recipients. Methods: We conducted a comprehensive literature search of Medline, Embase, and Maternity & Infant Care Database in December 2022. After screening, 54 relevant studies were identified. We also used data from the Transplant Pregnancy Registry International (TPRI). A total of 406 pregnancies from 271 heart recipients (HTR) and 143 pregnancies from 120 lung recipients (LTR) were included in the review. Results: 78.7% and 69% of pregnancies resulted in live births among HTR and LTR respectively (22% preterm). In HTR, graft dysfunction developed in 10.9% and 12.4% during and after pregnancy respectively. In LTR, 17.2% and 18% developed graft dysfunction during and after pregnancy. Other maternal complications included hypertensive disorders (HTR: 22.4%, LTR: 45.5%), preeclampsia (HTR: 9.1%, LTR: 14.5%) and diabetes (LTR: 15.9%, LTR: 31.4%). Maternal mortality was 17.1% for HTR and 29.3% for LTR. At the time of pregnancy approximately half of HTR and two thirds of LTR were on Tacrolimus. The most common immunosuppression changes were discontinuation of MMF, with and dose adjustment of Azathioprine, Sirolimus and corticosteroids. Conclusions: We found that, although the proportion of successful pregnancies among heart and lung transplant recipients reported in the literature was high, the risks of developing new graft dysfunction and of maternal death post pregnancy were substantial.
respiratory system
What problem does this paper attempt to address?